-
MSD begins KANDLELIT-007 trial of calderasib for NSCLC
08 Jan 2026 10:49 GMT
… metastatic nonsquamous non-small cell lung cancer (NSCLC).
Calderasib is an investigational … pemetrexed and chemotherapy (carboplatin or cisplatin).
Newly diagnosed patients with KRAS … 14% of all patients with lung cancer globally.
“By pairing our oral …
-
Association of Naples Prognostic Score with Survival in Patients with Inoperable Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy Combined with Immunotherapy
08 Jan 2026 02:27 GMT
… either fluorouracil combined with cisplatin or paclitaxel combined with … postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil … III non-small cell lung cancer. J Inflamm Res. … patients with small cell lung cancer and nomogram predictive model …
-
81 exceptional teen scientists of Indian-origin among 300 finalists of prestigious national competition
08 Jan 2026 01:04 GMT
… Robust and Practical Prediction of Cisplatin Response in Human Tumors
Samanyu … Hardly Reached? Investigating Use of Lung Cancer Screening Among Eligible U.S …
-
Evodiamine Targets Genes in Cisplatin-Resistant Lung Cancer
11 Dec 2025 08:45 GMT
… against cisplatin-resistant non-small cell lung cancer (NSCLC). Cisplatin, … significant fraction of lung cancer cases globally, … in oncologycisplatin-resistant lung cancer treatmentdifferential gene … therapynon-small cell lung cancer researchovercoming drug …
-
<![CDATA[Investigators Launch Phase 3 Trial of Calderasib Combo in Advanced NSCLC]]>
07 Jan 2026 21:47 GMT
… nonsquamous non–small cell lung cancer (NSCLC) harboring KRAS … cycle plus carboplatin or cisplatin on days 1 and … of all patients with lung cancer globally,” Gregory Lubiniecki, MD … .
Those with small cell lung cancer, active inflammatory bowel disease …
-
Korean team identifies ‘resistance switch’ in KRAS-mutated lung cancer
16 Dec 2025 06:48 GMT
… drive drug resistance in lung cancer.
Professor Shin Dong-hoon … of anticancer drugs in lung cancers harboring KRAS mutations. The … develops in KRAS-mutated lung cancer.
KRAS mutations are common … agents used in NSCLC—cisplatin and pemetrexed—the compound …
-
Hypoxia-Induced Autophagy Drives Lung Cancer Drug Resistance
12 Dec 2025 03:16 GMT
… of drug resistance in lung cancer treatment, researchers have … modulates cisplatin resistance in non-small cell lung cancer (NSCLC …
Non-small cell lung cancer remains a leading cause … autophagynon-small cell lung cancer treatmentnovel therapeutic approaches …
-
Cisplatin Boosts Lung Cancer Stem Cells via NF-κB
22 Nov 2025 02:51 GMT
… various cancers, including lung cancer. However, its clinical … to develop lung tumors, exposure to cisplatin resulted in … cells, NF-κB, cisplatin, lung cancer, DNA repair pathways, chemotherapy … lung cancerCisplatin and lung cancer treatmentcisplatin and tumor …
-
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
07 Jan 2026 12:16 GMT
… non-small cell lung cancer (NSCLC).
This … chemotherapy (carboplatin or cisplatin), in newly diagnosed … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
17 Dec 2025 13:34 GMT
… neoadjuvant chemotherapy (gemcitabine plus cisplatin) and surgery in patients … in combination with platinum (cisplatin or carboplatin) and … resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination … nonsquamous non-small cell lung cancer (NSCLC), with no …
About
© 1995-2026